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Lung transplant recipients who have persistent acute cellular rejection are 
at increased risk for the development ofchronic rejection, the leading cause 
of reduced long-term survival. This study evaluated the use of aerosolized 
cyclosporine as rescue therapy for unremitting acute rejection. Between 
June 1993 and March 1996, 18 patients with rejection that failed to resolve 
after therapy with pulse steroids and antilymphocyte globulin were enrolled 
in the study. Aerosolized cyclosporine A (300 mg) treatment was initiated 
for 10 consecutive days followed by a maintenance regimen of 3 days per 
week. Efficacy was assessed by graft histologic and pulmonary function 
testing. With the use of linear regression, results in these patients were 
compared with those in 23 control patients, matched for histologic acute 
rejection, who had continued to receive conventional rescue therapy. Two 
patients were unable to tolerate the treatments and were withdrawn from 
the study. Significant improvement in histologic rejection occurred in 14 of 
the remaining 16 patients after a mean of 37 days of aerosolized cyclospor- 
ine therapy. Measures of forced vital capacity and forced expiratory volume 
in 1 second (change in percent predicted/100 days plus or minus the 
standard error) increased over time in the treated patients whereas the 
condition of control patients declined despite repeated attempts at conven- 
tional rescue (forced vital capacity, aerosolized cyclosporine group, 4.6 --- 
2.9 vs control group -8.1 - 1.9, p = 0.001; forced expiratory volume in 1 
second, aerosolized cyclosporine group, 2.1 - 4.4 vs control group -9 .8  - 
2 .6 ,p  = 0.043). Renal and hepatic toxicity during cyclosporine therapy was 
not observed. The incidence of acute histologic rejection (_>A2) decreased 
from 2.49 - 0.68 episodes/100 days before aerosolized cyclosporine therapy 
to 0.72 - 0.3 episodes/100 days (p < 0.05). In summary, aerosolized cyc!ospor- 
ine is a safe and effective therapy for acute rejection that has failed to improve 
with conventional treatment. (J Thorac Cardiovasc Surg 1997;113:335-41) 
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T riple-drug regimens (cyclosporine or tacrolimus, azathioprine, prednisone) are routinely used as 
the maintenance therapy for lung transplant recipi- 
ents. Despite the success of these protocols, acute 
rejection affects more than 75% of patients. 14 Epi- 
sodes of acute cellular rejection are usually treated 
with short-term enhancement of immunosuppression 
consisting of pulse corticosteroids or cytolytic therapy. 
These efforts are not always successful and persistent 
or refractory acute rejection develops in many recipi- 
ents. 1-4 If acute rejection is not controlled it invariably 
results in tissue injury and organ failure. Persistent 
acute rejection is the predominant risk factor for the 
subsequent development of chronic rejection or death 
within the first year after transplantation)' 4, 6
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Table I. Patient demographics and lung function study results immediately before aerosolized cyclosporine 
therapy 
FVC FEVj FEF25_75 
Patient Age (yr) Sex Pre- Tx Dx Organs Day Rx L %* L %* L/sec % 
1 31 M PF L. single 91 1.25 23 1.20 28 2.26 51 
2 42 F PH R. single 246 3.31 98 2.62 100 2.41 78 
3 51 M COPD R. s!ngle 515 3.85 73 1.77 46 0.63 17 
4 24 F CF Double 190 2.32 61 1.86 60 1.91 53 
5 26 M PH Double 271 3.60 62 1.90 42 0.76 16 
6 53 F COPD R. single 386 2.06 69 .85 38 0.23 9 
7 26 F CF Double 339 2.57 78 1.92 72 1.54 47 
8 61 F COPD R. single 568 1.67 68 .82 46 0.19 8 
9 50 M COPD L. single 525 2.28 50 1.35 39 0.56 16 
10 52 F COPD R. single 275 2.18 73 1.15 51 0.44 16 
11 40 M CF Double 321 1.88 39 0.84 23 0.31 8 
12 43 M CF Double 782 3.20 61 3.02 76 4.17 104 
13 57 M COPD R. single 863 2.66 60 0.8 25 0.63 20 
14 55 F COPD R. single 398 1.27 45 0.79 38 0.45 18 
15 20 M CF Double 723 2.20 64 1.38 44 0.68 19 
16 28 M CF Double 816 3.78 88 2.95 82 2.58 61 
17 59 F COPD R. single 318 1.68 57 1.16 53 0.65 26 
18 43 F PH Double 767 2.11 62 1.94 75 3.07 104 
Mean 42 466 2.44 63 1.57 52 1.30 37 
Pre-Tx Dx, Diagnosis before lung transplantation; Day Rx, postoperative day treatment with aerosolized cyclosporine was initiated; FEF25_T5 , mean forced 
expiratory flow; M, male; PF, pulmonary fibrosis;/2, left; F, female; PH, pulmonary hypertension; R, right; COPD, chronic obstructive pulmonary disease; CF, 
cystic fibrosis. 
*Percent of predicted. 
In an attempt o address this issue we hypothe- 
sized that cyclosporine targeted directly into the 
allograft by aerosol inhalation would achieve a 
higher concentration than could be obtained by 
systemic delivery alone and would result in en- 
hanced control of rejection. This hypothesis was 
confirmed in our experimental model of rat lung 
transplantation] Our previous studies that used 
gamma camera imaging of radiolabeled aerosolized 
Cyclosporine indicated that high concentrations of
cyclosporine can be delivered to the lung allograft in 
recipients with chronic allograft rejectionS; however, 
the deposition pattern within the allograft is non- 
uniform. Subsequent studies showed that aerosol- 
ized cyclosporine can stabilize pulmonary function 
and reduce histologic inflammation i  patients with 
obliterative bronchiolitis. 9' 10 
In this study we evaluated the efficacy of aerosol- 
ized cyclosporine in the treatment of lung transplant 
recipients with acute cellular rejection that was 
refractory to conventional ugmented immune sup- 
pression. Response to therapy was assessed by 
changes in the histologic grade of rejection and by 
changes in pulmonary function during aerosol treat- 
ment. 
Methods 
Patient demographics. The protocol for this phase II 
trial was approved by the Institutional Review Board of 
the University of Pittsburgh and informed consent was 
obtained from each patient. Between June 1993 and 
March 1996, 18 consecutive recipients with persistent 
acute rejection were given aerosolized cyclosporine. Pa- 
tient characteristics are described in Table I. Entry into 
the study required refractory rejection as documented 
by transbronchial biopsy findings that persisted after 
multiple courses of pulse methylprednisolone a d equine 
lymphocyte immune globulin (ATGAM) (mean 6.8 -+ 
1.5 episodes). Acute rejection was considered signifi- 
cant if the grade was equal to or greater than grade 2.11 
On average the patients had approximately 466 days of 
follow-up after transplantation before initiation of aero- 
solized cyclosporine treatment. Twenty-three r cipients 
who had persistent refractory acute rejection before the 
development of aerosolized cyclosporine served as 
historical controls. Control patients were chosen to match 
for similar interval after transplantation, lung function, 
prevalence and treatment of rejection, type of lung 
transplant, age, and sex. Chronic rejection did not develop 
in any of these patients and they represent a different 
control population than the one used for a previous 
study? The incidence of acute rejection documented 
by transbronchial biopsy in this control population was 
on average 4.9 - 2.1 episodes over an average of 390 
days. 
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Immunosuppressive r gimen. Posttransplantation main- 
tenance immunosuppressive regimens for all patients con- 
sisted of oral cyclosporine (6 mg/kg per day, 7 recipients) 
or tacrolimus (0.30 mg/kg per day, 11 recipients), plus 
azathioprine (2 mg/kg per day) and prednisone (20 mg/ 
day). Oral doses of tacrolimus and cyclosporine were 
modified to maintain trough systemic levels at approxi- 
mately 15 to 20 ng/ml (enzyme-linked immunosorbent 
assay) and 800 to 1000 ng/ml (polyclonal TDX assay), 
respectively, immediately after transplantation and 
throughout the course of this trial. The azathioprine dose 
was reduced when the leukocyte count fell to less than 
5.0 X 106/L. Enhanced immune suppression for treatment 
of acute rejection (>grade 2) consisted of either pulse 
methylprednisolone (1.0 gin/day for 3 days intravenously) 
or equine lymphocyte immune globulin (ATGAM) (20 
mg/kg per day for 14 days intravenously) 
Histologic assessment of rejection (before aerosol cy- 
closporine treatment). Fiberoptic bronchoscopy was rou- 
tinely done approximately 2 weeks after transplantation 
and at 3-month intervals thereafter to detect asymptom- 
atic rejection or infection. Transbronchial biopsy is recog- 
nized as an excellent means of detecting the vascular 
mononuclear infiltrate of acute rejection in the allograft 
and differentiating rejection from infection. 12' 13 Biopsy 
was done whenever changes in clinical or functional 
parameters such as oxyhemoglobin saturation, spir0metry 
values (>10% decline of forced vital capacity [FVC] or 
forced expiratory volume in 1 second [FEV~]), or chest 
radiographic findings occurred and at 4 to 6 weeks after 
pulse corticosteroid therapy and 6 to 8 weeks after equine 
lymphocyte immune globulin therapy to assess a treat- 
ment response. Acute cellular ejection was graded as A1 
to A4 to indicate minimal, mild, moderate, or severe 
disease. 1~ Pathologists who interpreted biopsy samples 
were blinded tO the immunosuppressive drug regimen. 
Drug preparation, aerosol generation, and treatment 
protocol. Aerosolized cyclosporine was given with use of a 
commercially available jet nebulizer (Aero Tech II, Cis- 
Us, Bedford, Mass.) driven by compressed air (50 psi) at 
a flow rate of 10 L/min) 4 Three hundred milligrams of 
cyclosporine (Sandoz, Basel, Switzerland) was dissolved in 
4.8 ml propylene glycol. Inhalation was done through a 
mouthpiece during spontaneous respiration. Treatments 
were given with use of a commercially available high- 
efficiency particulate air filter tO ensure absence of envi- 
ronmental coinLtamination (AeroStar, Bi0Safety Systems, 
San Diego, Calif.). 
Patients were premedicated by inhalation of 2% lido- 
caine (5 ml) via a conventional nebulizer after which they 
received the aerosolized cyclosporine at a dosage of 300 
mg per day. Daily peripheral blood samples were drawn 
for determination of trough cyclosporine concentrations 
and levels of creatinine and liver enzymes 24 hours after 
inhalation for the first 12 days of therapy. After comple- 
tion of the initial 10-day schedule, treatments were given 
at home 3 days per week at 300 mg per session. 
Follow-up and outcome measures. Fiberoptic bron- 
choscopy with transbronchial biopsy was done under 
fluoroscopic guidance at approximately 4 weeks after the 
start of aerosolized cyclosporine therapy and then at 2- to 
3-month intervals. A minimum of 10 tissue samples was 
obtained with alligator forceps at the same anatomic 
location (anterior, lateral, posterior basilar, or anterome- 
dial, lateral, and posterior basilar segments of the right or 
left lower lobe, respectively) where acute rejection was 
detected before aerosolized cyclosporine therapy. Cyclo- 
sporine blood levels were measured and renal and liver 
function tests were done at 14-day intervals after dis- 
charge from the hospital. Pulmonary function tests and 
chest radiographs were done monthly and blood pressure 
and home spirometry values were measured by each 
patient and recorded aily. 
Pharmacokinetics tudies. To assess ystemic absorp- 
tion of aerosolized cyclosporine, blood cyclosporine l vels 
were measured in four patients receiving oral tacrolimus 
as maintenance therapy. On the seventh day of aerosol 
treatment a trough cyclosp0rine l vel was obtained, fol- 
lowed by samples drawn on completion of the dose and at 
20 minutes, 40 minutes, and 1, 2, 4, 8, and 24 hours after 
completion of the dose. Samples were analyzed by high- 
performance liquid chromatographyJ s 
Statistical analysis. Random effects linear regression 
analysis was used to compare slopes of the FVC and FEV 1 
values after transplantation i  the 18 patients who re- 
ceived aerosolized cycl0sporine and in 23 control patients. 
In this regression model, pretreatment and posttreatment 
population slopes calculated for the aerosolized cyclo- 
sporine and control populations were analyzed for statis- 
tically significant slope differences (p < 0.05). For each 
pulmonary function test, we tested for a difference in the 
pretreatment period to determine whether to adjust for 
baseline differences between groups. Finding none, we 
fitted regression models to all subjects and tested for 
differences in population slopes in the posttreatment 
period. A Student's t test was used to compare changes in 
the FVC, FEV1, and mean forced expiratory flow values 
immediately before and after approximately 200 days of 
aerosolized cyclospofine therapy. The rate of histologic 
rejection was compared before the start of aerosolized 
cyclosporine therapy and during maintenance a rosolized 
cyclosporine therapy with a Wilcoxon signed-rank test. 
Results are expressed as mean plus or minus the standard 
deviation. 
Results 
Changes in allograft histologic features during 
aerosolized cyclosporine therapy. All patients had 
grade 2 or higher rejection before treatment. Two of 
the patients (patients 10 and 14) were unable to 
tolerate the aerosol treatments because of intracta- 
ble cough and airways irritation and had to be 
withdrawn from the trial. In 14 (88%) of the remain- 
ing 16 subjects, the degree of histologic inflamma- 
tion of acute rejection significantly diminished to 
minimal levels (A1) or disappeared (A0) with the 
institution of aerosolized cyclosporine therapy (Ta- 
ble II). One pediatric patient (patient 15) had only 
modest improvement as shown on the treatment 
biopsy results but was given continued therapy with 
subsequent improvement in pulmonary function 
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Table II. Histologic changes in severity of rejection 
among 18 consecutive patients immediately before 
and during aerosolized cyclosporine therapy 
Histologic grade 
Aerosol 
Patient Pretreatment During treatment treatment days* 
1 A3 A0 32 
2 A2 A0 29 
3 A3 A3 20 
4 A2 A0 37 
5 A2 A0 39 
6 A2 A0 70 
7 A2 A0 9 
8 A3 A1 12 
9 A2 A1 36 
10t A4 A3 21 
11 A3 A0 38 
12 A3 A1 63 
13 A3 A1 38 
14t A3 A3 37 
15 A4 A3 10 
16 A2 A0 78 
17 A2 A1 47 
18 A2 A1 57 
*Grades of acute rejection (A0 through A4) are described in the text. 
Aerosol treatment days refers to duration of treatment before the fol- 
low-up biopsy was done. 
?Patients 10 and 14 were unable to tolerate the aerosol treatments and 
were withdrawn from the trial. 
testing results. Further biopsies have not been done. 
The other patient (patient 3) has not had any 
histologic improvement but has stabilized pulmo- 
nary function and so has been given continued 
therapy. 
Sustained improvement inhistologic rejection was 
seen in serial biopsy samples: the incidence of acute 
rejection (grade A2 or greater) decreased from 
2.49 ± 0.68 per 100 patient days before therapy with 
aerosolized cyclosporine to 0.72 ± 0.3 per 100 
patient days during therapy (p < 0.05). Patients have 
received aerosol treatments for an average of 187 
days (range 105 to 246 days). Discontinuation of 
aerosolized cyclosporine was attempted in five pa- 
tients but resulted in recurrence of histologic rejec- 
tion in four of five recipients. 
Pulmonary function before and during aerosol- 
ized cyclosporine therapy. To demonstrate he ef- 
fect of aerosolized cyclosporine on pulmonary func- 
tion, changes in FVC and FEV 1 values were 
compared at similar intervals after lung transplan- 
tation in the 18 treated subjects and 23 matched 
control patients who had continued to receive con- 
ventional therapy (Fig. 1). Measures of FVC and 
FEV 1 (change in percent predicted/100 days plus or 
minus the standard error) increased over time in the 
patients treated with aerosolized cyclosporine 
whereas pulmonary function in control patients de- 
clined despite repeated attempts at conventional 
rescue (FVC, aerosolized cyclosporine group, 4.6 +_ 
2.9 vs control group, -8.1 _+ 1.9,p = 0.001; FEV1, 
aerosolized cyclosporine group, 2.1 + 4.4 vs control 
group, -9.8 ± 2.6, p = 0.043). 
Pharmacokinetics of systemic cyclosporine after 
aerosolized inhalation. In four patients receiving 
oral tacrolimus, cyclosporine blood levels were mea- 
sured during daily treatment with aerosolized cyclo- 
sporine at a 300 mg dose. The average maximal 
blood level (by high-performance liquid chromatog- 
raphy) within 60 minutes of inhalation was 225 ± 
132 ng/ml (range 140 to 419 ng/ml). Cyclosporine 
concentrations progressively decreased such that 
after 24 hours the mean trough cyclosporine level 
was 23 ± 17 ng/ml (range 37 ng/ml to nondetect- 
able). Renal function did not change significantly 
with the addition of aerosolized cyclosporine to the 
baseline immunosuppressive drug regimen. 
Discussion 
In this study we have shown that aerosolized 
cyclosP0rine was effective rescue therapy in 14 of 18 
consecutive lung allograft recipients with unremit- 
ting histologic acute rejection. These patients had 
been given multiple courses of pulsed corticoste- 
roids and antilymphocyte globulin but this therapy 
had failed to achieve a therapeutic response. Our 
previous trials had primarily concentrated on pa- 
tients with refractory chronic rejection. 9'10 In these 
studies, treatment with aerosolized cyclosporine re- 
sulted in stabilization of pulmonary function as the 
histologic features of active inflammation improved. 
Application of this therapy in the treatment of 
persistent acute rejection is particularly important 
because of the significance of persistent acute rejec- 
tion as a risk factor for the development of obliter- 
ative bronchiolitis. 6 
The results of this present study show that impor- 
tant definitive reductions in the histologic infiltrates 
of acute allograft rejection occurred on initiation of 
aerosolized cyclosporine therapy. Moreover, the 
changes observed in allograft histologic features 
during aerosolized cyclosporine therapy were asso- 
ciated with improvement in the spirometric indices 
of lung function. In contrast o findings in patients 
treated with aerosolized cyclosporine, a progressive 
decline in lung function was observed in a matched 
control population treated with conventional rescue 
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Fig. L Population regression lines showing changes in values of FEV 1 and FVC (percent predicted) 
before and during 200 days of aerosolized cyclosporine therapy in 18 subjects and 22 control recipients, 
matched by prevalence of rejection, who received pulse methylprednisolone a d cytolytic therapy. For the 
18 subjects treated with aerosolized cyclosporine the percent predicted FEV 1 value actually improved 
whereas there was no comparable interruption i the decline in values of either FVC (p = 0.001) or FEV~ 
(p = 0.043) in the control population. 
immunosuppression. These results indicate that in- 
haled cyclosporine is more effective than pulsed 
methylprednisolone and antilymphocyte globulin in 
reversing persistent acute histologic rejection. The 
effects of aerosol treatment appear to be sustained 
because repeated transbronchial biopsy samples ob- 
tained at defined intervals have shown consistent 
reductions in the grades of acute rejection. 
The most frequent adverse ffect related to aero- 
solized cyclosporine treatment consisted of cough 
and transient dyspnea. Although most subjects had 
these effects during inhalation, only two patients 
required premature discontinuation of the treat- 
ment. These two patients do, however, demonstrate 
that airways irritation may be severe enough to limit 
the use of aerosolized cyclosporine in some recipi- 
ents. 
The absence of significant systemic absorption 
after inhalation of cyclosporine would probably ac- 
count for the lack of renal and hepatic toxicity in our 
study population. We have also shown that whole 
blood levels of cyclosporine are minimal after inha- 
lation of a 300 mg dose of cyclosporine. These 
results upport our hypothesis that the inhaled route 
of administration for cyclosporine A is safe. 
The efficacy of aerosolized cyclosporine therapy 
has encouraged us to embark on a prospective 
randomized trial of this agent compared with stan- 
dard rescue treatments. Our protocol will compare a
limited course of aerosolized cyclosporine versus 
methylprednisolone when the second episode of 
acute rejection is documented. All patients will 
receive methylprednisolone for a first rejection 
event. All patients will undergo transbronchial bi- 
opsy with histologic and cytokine analysis of bron- 
choalveolar lavage fluid and peripheral blood. Sub- 
jects who receive aerosolized cyclosporine will also 
undergo testing to measure the regional deposited 
amounts of inhaled cyclosporine within the trans- 
planted lung or lungs and to correlate these findings 
with changes in histologic rejection and alterations 
of cytokine gene expression. The protocol calls for a 
limited (8 to 12 weeks) treatment course with aero- 
solized cyclosporine. Patients in both groups who 
have treatment failure will be given cytolytic ther- 
apy. 
hnprovements in the histologic grade of rejection 
after aerosolized cyclosporine therapy appear to 
correlate with downregulation of proinflammatory 
cytokine gene expression for interleukin-6 and in- 
terferon-7 in cells of bronchoalveolar lavage fluid. 1° 
This immunomodulation may also account for the 
stabilization of pulmonary function measures in the 
two patients in whom histologic resolution was not 
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seen. The proposed randomized trial should yield 
better information to elucidate the mechanism of 
action of this agent. 
It is recognized that there are regional differences 
in cytokine expression, and, similarly, varying de- 
grees of severity of rejection within the lung allo- 
graft have been documented. In addition, deposition 
of aerosolized drug within the lung is clearly not 
uniform, s Under the proposed protocol, biopsy 
specimens will be obtained from various sites ac- 
cording to the deposition studies. This information 
will be necessary to determine the optimal candi- 
dates for aerosolized cyclosporine therapy and to 
maximize efficacy of this therapy. 
This study has demonstrated that aerosolized 
cyclosporine was more effective than conventional 
treatment in suppressing the inflammatory response 
in the allograft of lung transplant recipients with 
refractory acute rejection. We speculate that aero- 
solized cyclosporine also has the potential to allow 
reduction in oral doses of immunosuppressive 
agents thereby further reducing the risk of infection 
and systemic toxicity. Ultimately, improved control 
of acute rejection with aerosolized cyclosporine may 
prevent the subsequent phase of chronic allograft 
rejection, which is characterized by irreversible lung 
injury as a result of fibrosis in the transplanted lung. 
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Discussion 
Dr. Sara J. Shumway (Minneapolis, Minn.). We know 
that the efficacy of aerosol therapy is influenced by a 
number of variables. These include the type of nebulizer 
device used to deliver the aerosol, the physical properties 
of the drug, its concentration i the aerosol and particle 
size, its carrier gas, and the somewhat nebulous catch-all 
known as patient factors. From previous tudies, primarily 
by the Pittsburgh group, we know that pulmonary depo- 
sition of cyclosporine has been demonstrated after aero- 
solized cyclosporine administration. It appears to accumu- 
late in the trachea, bronchi, and regional ymph nodes as 
well. 
This study reports findings in a relatively small group of 
patients without a real control group. If the authors were 
to initiate randomized controlled trials with aerosolized 
cyclosporine, what would they test it against? Methotrex- 
ate has been used with some benefit in certain patients. 
What about photopheresis? 
The maintenance protocol the authors used may re- 
quire modification. Perhaps these patients need to be 
given more oral cyclosporine rather than receiving it in the 
aerosolized form. Three hundred milligrams is quite a lot 
of cyclosporine. What sort of cyclosporine levels occur 
when the patients are receiving both oral and aerosolized 
cyclosporine? The cost of the added aerosolized cyclo- 
sporine is yet another consideration. 
Finally, I believe the real target population for aerosol- 
ized cyclosporine therapy may be patients who undergo 
bilateral single-lung or heart-lung transplantation because 
of cystic fibrosis. They are usually used to receiving 
antibiotics in this fashion before transplantation a d have 
trouble with adequate absorption after oral ingestion of 
cyclosporine. This paper presents an excellent pilot study 
that demonstrates this treatment option for persistent 
acute lung allograft rejection. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 2 
Keenan et al. 341  
Dr. Keenan. We did not mention in the presentation 
here a proposal that we have been debating on whether to 
randomize these patients much earlier in the course of the 
transplantation treatment. After the first episode of rejec- 
tion treated by standard therapy, should we then go on to 
using aerosolized cyclosporine in place of yet another 
dose of methylprednisolone or, potentially, cytolytic ther- 
apy? We are looking at this issue of where the potential 
role of aerosolized cyclosporine lies. 
We also have been using alternative therapies to deal 
with persistent or refractory rejection. We have been 
using methotr,exate in a number of patients. Photophere- 
sis is available, although it too is expensive. The kits are 
available, but 1;he time it takes for delivery and so on leads 
to a considerable expense. Also, although there have been 
a few patient series reported and anecdotal reports of this 
therapy in lung transplant recipients, it, too, is in a sense 
an experimental therapy, and therefore to use one exper- 
imental therapy and judge it against another experimental 
therapy I think would be stretching the issue. That is why 
we have chosen to go this route, which is the gold 
standard, if you will, of methylprednisolone or antithymo- 
cyte globulin versus aerosolized cyclosporine. 
In terms of the inhalation of these agents, we too were 
concerned, particularly early on, that the single-lung re- 
cipients with the intact native lung and the intact neuro- 
conduits would be less able to tolerate the solution, and, in 
fact, this is what we found in several patients who had 
chronic rejection. In the patients with acute rejection, that 
has not been as consistent a problem, and of the two 
patients in whom the therapy had to be discontinued, one 
was a double-lung recipient and one was a single-lung 
recipient. Thus we have not yet found the need to 
discriminate between single- and double-lung recipients in 
terms of delivery of the agent. 
We have done a considerable amount of work with a 
colleague, Jerry Smaldone, in Stow Brook to examine the 
issue of particle size and distribution. His work with 
radio-tagged albumin as a correlate to the inhaled cyclo- 
sporine shows that the vast majority of this drug is 
deposited into the parenchyma with a mean aerodynamic 
diameter of approximately 1.2 /xm, and this is fairly 
consistent. The beauty of the particular nebulizer that we 
are using is that one can show that the particle size 
distribution does not change from the beginning of the 
nebulized treatment to the end of the treatment; hus we 
are getting a consistent pattern of deposition. 
I cannot ell you exactly the levels of cyclosporine in all 
of these patients. What I can tell you is that we use a TDX 
method for our cyclosporine surveillance and maintain the 
level between 800 and 1000 ng/ml, and we did not have to 
adjust the systemic yclosporine level in any of the pa- 
tients to account for the increased absorption from the 
aerosol. 
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